Infliximab Paediatric Crohn’s Disease Educational Plan: A European, Cross-Sectional, Multicentre Evaluation

Background: The infliximab (Remicade®; Schering-Plough, Kenilworth, NJ, USA) Risk Management Plan included the development, execution and tracking of an education programme directed towards prescribers of infliximab for patients with paediatric Crohn’s disease (the Infliximab Paediatric Crohn’s Dise...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug safety 2010-06, Vol.33 (6), p.489-501
Hauptverfasser:	Arana, Alejandro, Allen, Sam, Burkowitz, Jörg, Fantoni, Valerio, Ghatnekar, Ola, Rico, María Teresa, Vanhaverbeke, Nathalie, Wentworth, Charles E., Brosa, Max, Arellano, Felix M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse Drug Reaction Reporting Systems Antibodies, Monoclonal - adverse effects Biological and medical sciences Child Children Crohn Disease - drug therapy Crohn's disease Databases as Topic Demographic aspects Diagnosis Diseases Dosage and administration Drug Safety and Pharmacovigilance Drug therapy Education, Medical - methods Europe Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Agents - therapeutic use Guideline Adherence - statistics & numerical data Health aspects Humans Immunomodulators Infliximab Medical sciences Medicine Medicine & Public Health Methods Miscellaneous Mycobacterium Observational studies Original Research Article Other diseases. Semiology Pharmacology. Drug treatments Pharmacology/Toxicology Practice Patterns, Physicians' - statistics & numerical data Prevalence studies (Epidemiology) Program Evaluation Public health administration Public health. Hygiene Public health. Hygiene-occupational medicine Risk Management - methods Staff Development - methods Staff Development - statistics & numerical data Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!